Document:

<PAGE>

                                                                   Exhibit 10.18

                        SEPARATION AND RELEASE AGREEMENT

     THIS SEPARATION AND RELEASE AGREEMENT (this "Agreement"), dated July 8,
2002, is entered into by SEEC, INC. (hereinafter referred to as "SEEC") and
BRUCE W. CAMERON ("Cameron").

                              W I T N E S S E T H :

     WHEREAS, SEEC and Cameron are parties to an Amended Employment Agreement
dated October 1, 2001 pursuant to which Cameron has been employed as Senior Vice
President - Worldwide Sales and Services (the "Employment Agreement"); and

     WHEREAS, Cameron and SEEC have agreed to terminate their working
relationship and the Employment Agreement effective on September 30, 2002 and to
modify the terms thereof in the manner set forth herein.

     NOW, THEREFORE, in consideration of the promises contained herein, and with
the intent to be legally bound, the parties agree as follows:

     1. TERMINATION OF EMPLOYMENT. Effective on September 30, 2002, Cameron
shall cease to be an employee of SEEC and the parties hereby confirm that the
Employment Agreement will be terminated as of that date.

     2. MODIFICATION OF DUTIES. Commencing on the date hereof, notwithstanding
anything in the Employment Agreement to the contrary, Cameron shall not direct
SEEC's sales force or have any responsibility for formulating sales policies or
strategies. Cameron's duties shall be limited to assisting SEEC with
transitioning his duties and responsibilities to other SEEC personnel, assisting
SEEC in closing its pipeline of business, training sales personnel and other
duties reasonably requested by the President of SEEC.

     3. TERMINATION OF BENEFITS. Cameron agrees that payment of all salary and
benefits, as well as his participation in all employee benefit plans of SEEC,
shall cease and terminate as September 30, 2002.

     4. INCENTIVE STOCK OPTIONS. The parties confirm that SEEC has heretofore
granted to Cameron incentive stock options for 100,000 shares of SEEC Common
Stock pursuant to SEEC's 1997 Stock Option Plan. As of September 30, 2002,
options for 32,500 of such shares will have vested. Cameron's options for these
32,500 shares shall be exercisable until September 30, 2003 and will terminate
if not exercised on or before that date in accordance with the 1997 Stock Option
Plan. Cameron hereby surrenders and forfeits to SEEC all of his outstanding
stock options for the remaining 67,500 shares, all of which are hereby canceled
and no longer exercisable.

     5. SEVERANCE BENEFIT. The parties agree that Cameron is entitled to the
"Severance Benefits" set forth in Section 6.3 of the Employment Agreement.
Accordingly, SEEC shall pay Cameron $90,000, payable in twelve (12) semi-monthly
installments of $7,500 at SEEC's regularly scheduled pay dates, beginning
October 15, 2002 and extending to and including the pay date of March 31, 2003.
Each payment will be subject to applicable withholding taxes.

     6. INCENTIVE COMPENSATION PLAN. Commencing on July 8, 2002 and ending on
September 30, 2002, Cameron will be entitled to participate in the incentive
compensation plan set forth on Exhibit A hereto. This incentive compensation
plan supercedes and replaces any incentive compensation, bonus or

<PAGE>

Separation and Release Agreement
July 8, 2002

similar plan in which Cameron currently participates, including without
limitation, those set forth in the Employment Agreement.

     7. RELEASE. Without limiting the other provisions of this Agreement,
Cameron, for and on behalf of himself, his heirs, executors, administrators,
successors and assigns, hereby fully and finally releases and discharges SEEC,
its shareholders, investors, predecessors, subsidiaries and affiliated companies
and its and their officers, directors, shareholders, employees and agents, and
its and their respective successors and assigns (hereinafter collectively
referred to as the "SEEC Released Parties"), of and from any and all manner of
action, causes of action, legal proceedings, lawsuits, dues, accounts, bonds,
covenants, contracts, agreements and compensation (including without limitation
stock options), whether in law or in equity, in contract or in tort, under
statute or at common law, whether now known or unknown, which Cameron ever had
or now has by reason of any matter, cause or thing whatsoever from the beginning
of the world to the date of this Agreement arising from, or in any way relating
to, the employment relationship between Cameron and SEEC, the Employment
Agreement, the termination of his employment relationship with SEEC or his
affiliation with the SEEC Released Parties (but not this Agreement). This
release includes, but is not limited to, any and all claims under Pennsylvania
Human Relations Act, Title VII of the Civil Rights Act of 1964, as amended, 42
U.S.C. ss.2000, ET SEQ., the Age Discrimination in Employment Act, 29
U.S.C. ss.601, ET SEQ., the Americans with Disabilities Act, and any claims for
attorneys' fees under these acts or any other law.

     8. RELEASE. SEEC hereby fully and finally releases and discharges Cameron
and his heirs, executors, administrators and assigns, of and from any and all
manner of actions, causes of action, legal proceedings, lawsuits, dues,
accounts, bonds, covenants, contracts and agreements, whether in law or in
equity, in contract or in tort, under statute or at common law, whether now
known or unknown, which SEEC ever had or now has by reason of any matter, cause
or thing whatsoever from the beginning of the world to the date of this
Agreement arising from, or in any way relating to, the employment relationship
between Cameron and SEEC, the Employment Agreement, or the termination of his
employment relationship with SEEC (but not this Agreement).

     9. CONFIDENTIALITY. Both SEEC and Cameron will keep the terms of this
Agreement confidential and will not communicate or disclose such terms to any
individual or entity, except their attorneys, or, in Cameron's case, to his
spouse, financial adviser, attorney or accountant, or in SEEC's case, to
individuals reasonably required to implement this Agreement. Prior to any
disclosure permitted in the preceding sentence, the party making such disclosure
shall inform the recipient that the information shall be treated as confidential
and that the recipient shall be similarly bound by that commitment.

     10. COVENANTS. Without limiting the foregoing, Cameron agrees to hold and
safeguard all confidential and proprietary information of SEEC in trust for SEEC
and its successors and assigns and agrees that he shall not misappropriate,
disclose or use for any reason or purpose, or make available to anyone for use
at any time for any reason or purpose, any of such confidential or proprietary
information, whether or not developed by Cameron during the course of his
employment by SEEC, and Cameron agrees not to solicit or induce, or attempt to
solicit or induce, any employee of SEEC to leave SEEC for any reason whatsoever.

     11. SURVIVAL OF EMPLOYMENT AGREEMENT PROVISIONS. The parties acknowledge
and agree that, without limiting the provisions hereof, pursuant to Section 6.5
of the Employment Agreement, Section 3 (Inventions, Discoveries and
Improvements) and Section 4 (Confidentiality of Proprietary Data) shall survive
termination of the Employment Agreement.

                                       -2-
<PAGE>

Separation and Release Agreement
July 8, 2002

     12. RETURN OF COMPANY PROPERTY. Cameron hereby agrees to promptly, but in
any event no later than 5:00 p.m. on September 30, 2002, deliver to SEEC all
property in his possession owned or leased by SEEC, including without limitation
the automobile, personal computer, fax machine and SEEC credit cards provided to
Cameron by SEEC and any unused airline tickets. Meanwhile, Cameron shall have
access to his current office and any SEEC computers and other equipment
necessary to perform his duties hereunder. SEEC agrees to reimburse Cameron for
any unreimbursed travel and other expenses upon submission by Cameron to SEEC of
appropriate documentation evidencing the same.

     13. RIGHT TO COUNSEL. BY EXECUTING THIS AGREEMENT, CAMERON HEREBY
ACKNOWLEDGES THAT SEEC HAS ADVISED HIM THAT HE HAS TWENTY-ONE (21) DAYS FROM THE
DATE HE FIRST RECEIVED THIS AGREEMENT TO CONSULT AN ATTORNEY REGARDING THE TERMS
AND CONDITIONS OF THIS AGREEMENT. CAMERON FURTHER ACKNOWLEDGES THAT SEEC HAS
URGED HIM TO SEEK LEGAL COUNSEL IN REGARD TO THE TERMS AND CONDITIONS OF THIS
AGREEMENT AND HAS ALSO ADVISED HIM THAT HE HAS SEVEN (7) DAYS AFTER THE DATE OF
THE EXECUTION OF THIS AGREEMENT TO REVOKE HIS ACCEPTANCE OF THIS AGREEMENT.

     14. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement and
understanding of the parties and supersedes all prior oral and written
agreements or understandings between the parties. The provisions of this
Agreement are severable, and if any part of it is found to be unenforceable, the
other paragraphs shall remain fully valid and enforceable.

     15. GOVERNING LAW. This Agreement shall be construed by and enforced in
accordance with the laws of the Commonwealth of Pennsylvania.

     IN WITNESS WHEREOF, and intending to be legally bound, the undersigned have
hereunto set their hands and seals this 19th day of July, 2002.

                                                     SEEC, INC.

                                            By: /s/  Ravindra Koka
                                                --------------------------------

                                                /s/  Bruce W. Cameron
                                                --------------------------------

                                      -3-<PAGE>

                                                                    EXHIBIT 10.1

                              AGREEMENT AND RELEASE

         WHEREAS, DEMETER BIOTECHNOLOGIES, LTD and/or DEMEGEN, INC. (hereinafter
"Demegen") and MYCOGEN CORPORATION and/or DOW AGROSCIENCES LLC (hereinafter
"Mycogen") were parties to a certain Restated Demeter-Mycogen License and
Royalty Agreement, effective September 23, 1997 (the "1997 Agreement") and to a
certain Addendum to the Restated Demegen-Mycogen License and Royalty Agreement,
effective October 10, 1998 (the "1998 Addendum");

         WHEREAS, Demegen has asserted claims and allegations against Mycogen in
a certain arbitration proceeding (the "Arbitration") pending before Technology
Mediation Services, LLC, Sandra A. Sellers presiding (the "Arbitrator");

         WHEREAS, Demegen has alleged Mycogen breached the 1997 Agreement and
the 1998 Addendum;

         WHEREAS, Mycogen disputes the claims and allegations made against it by
Demegen;

         WHEREAS, Mycogen has asserted that it was entitled to a return from
Demegen of certain payments made to Demegen;

         WHEREAS, Demegen disputes the claims and allegations made against it by
Mycogen; and

         WHEREAS, to avoid the uncertainties inherent in the Arbitration, and in
order to purchase peace between themselves, and neither party admitting fault or
liability or the merits of their respective positions, each as against the
other, Demegen and Mycogen agree to settle and resolve the disputes between
them, fully and forevermore, according to the terms and conditions as set forth
below.

         NOW, Therefore, in exchange for and in consideration of the mutual
promises herein set forth, and intending to be bound thereby, Demegen and
Mycogen agree as follows:

         1. On or before June 17, 2002, Mycogen will pay Demegen six hundred
fifty thousand dollars ($650,000) as final research payments and partial
reimbursement of legal expenses.

         2. On or before June 17, 2002, Mycogen will pay DeForest & Koscelnik a
separate sum in the amount of one hundred fifty thousand dollars ($150,000).

         3. On or before June 17, 2002, Mycogen will pay Demegen the amount of
thirteen thousand dollars ($13,000) as reimbursement of the Arbitrator's
retainer previously paid by Demegen. Should any portion of the thirteen thousand
dollars ($13,000) paid by Demegen to the Arbitrator be reimbursed, said funds
will belong to Mycogen. Mycogen will pay any additional charges by the
Arbitrator, related to the Arbitration.

<PAGE>

         4. On or before June 17, 2002, Mycogen will pay Demegen a separate sum
in the amount of forty-three thousand four hundred forty-two dollars ($43,442)
attributable to patent expenses which are the obligation of Mycogen under the
1997 Agreement.

         5. Demegen agrees that Mycogen has made or committed herein to make all
payments required under the 1997 Agreement and/or the 1998 Addendum. Mycogen
agrees that Demegen shall not be required to return to Mycogen any prior
payments made by Mycogen.

         6. The parties stipulate and agree that the 1997 Agreement was properly
terminated under Article XIX thereof on April 30, 2002, and that the 1998
Addendum was properly terminated under Article XIII thereof on March 15, 2002,
and that all further and future rights, responsibilities and obligations between
them thereunder are as provided in the 1997 Agreement and the 1998 Addendum.

         7. Mycogen represents and warrants that no licenses, sublicenses, or
assignments of rights have been made under the 1997 Agreement or the 1998
Addendum.

         8. Demegen and Mycogen agree that CRADA #58-3K95-M-669 which expires
July 20, 2002, should be completed by Mycogen.

         9. Demegen represents and warrants that it has not disclosed to Mycogen
any confidential information or trade secrets to which it asserts any
proprietary and/or pecuniary interest, or for which it is entitled to
compensation or further consideration of any kind or type other than the
payments as set forth herein, except as stated on the attached Exhibit "1" and
to the extent the information associated with the patent applications referenced
in said Exhibit "1" is not published by issuance of patents relating thereto,
and the amino acid sequences on Attachment A to Exhibit "1" have not been or do
not become published or communicated to Mycogen by a third party having the
legal right to do so.

         10. Demegen, for itself and its past or present parent corporations,
subsidiaries, successors and assigns, does hereby irrevocably and
unconditionally release, remise, settle, compromise and forever discharge
Mycogen and any of its past or present parent corporations, subsidiaries,
representatives, agents, attorneys, officers and employees, and their heirs,
successors and assigns, from any and all liability, actions, causes of action,
judgments, claims, damages and demands of whatsoever kind and nature (including
but not limited to attorneys fees, expenses and costs) which they have or may
have or claim to be entitled to, arising from any actual or alleged actions or
failures to act, known or unknown, up to and including the date of execution
hereof, which are or might be alleged to be a breach of the 1997 Agreement
and/or the 1998 Addendum.

         11. Mycogen, for itself and its past or present parent corporations,
subsidiaries, successors and assigns, does hereby irrevocably and
unconditionally release, remise, settle, compromise and forever discharge
Demegen and any of its past or present parent corporations, subsidiaries,
representatives, agents, attorneys, officers and employees, and their heirs,
successors and assigns, from any and all liability, actions, causes of action,
judgments, claims, damages and demands of whatsoever kind and nature (including
but not limited to attorneys fees, expenses and costs) which they have or may
have or claim to be entitled to, known or unknown, arising from any actual or
alleged actions or failures to act, up to and including the date of execution
hereof, which are or might be alleged to be a breach of the 1997 Agreement
and/or the 1998 Addendum.

                                      -2-
<PAGE>

         12. Demegen's claims in the Arbitration before the Arbitrator are
hereby withdrawn and terminated with prejudice. Demegen will execute any and all
additional documents reasonably necessary, if any, to effectuate the termination
of the Arbitration.

         13. Neither party will disclose the substantive terms of this Agreement
and Release other than (a) to counsel, accountants, potential investors,
acquirers, business partners or further as necessary to assert their legal
rights or discharge their legal obligations (including, but not limited to,
disclosure to comply with the securities laws or disclosure to Louisiana State
University), (b) in a statement mutually agreed between the parties, provided
that agreement thereto shall not be unreasonably withheld, or (c) Demegen may
advise that amounts in its financial statements are attributable to an amicable
resolution of issues relating to the 1997 Agreement and the 1998 Addendum.

         14. There are no understandings between the parties regarding this
Agreement and Release other than as specifically set forth herein and there have
been no promises, inducements or commitments made in conjunction with this
Agreement and Release which are not explicitly set forth herein.

         15. THE UNDERSIGNED HEREBY ACKNOWLEDGE THAT THEY HAVE READ THIS
AGREEMENT AND RELEASE, CONFERRED WITH THEIR ATTORNEYS, AND UNDERSTAND THAT, BY
SIGNING THIS AGREEMENT, THEY HAVE MADE THE COMMITMENTS AND RELEASED THEIR RIGHTS
AS STATED ABOVE.

         16. The undersigned intend for the party, upon behalf of which they
execute, to be legally bound by this Agreement and Release and have read,
signed, sealed and delivered it voluntarily, without coercion, with knowledge of
the nature and consequences thereof and with the power to legally commit that
party.

                          MYCOGEN CORPORATION and/or DOW
                          AGROSCIENCES LLC

                          DEMETER BIOTECHNOLOGIES, LTD and/or DEMEGEN, INC.

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]